FORMULATING


BRIGHTENING (%)


Placebo 2% Col-Frag Remastered™


18% *** ***


9% # *


3% #


T7 days Up to:


+26% in 7 days +47% in 28 days


2% T14 days 4% T28 days T7 days


Up to: +38% in 7 days +62% in 28 days


T14 days T28 days


+26% after 28 days in 100% volunteers


Figure 3: Comparison of brightening effects of three formulations using 2% Col-Frag Remastered, 2% Ascorbyl Glucoside, and 1% each of Col-Frag Remastered and Ascorbyl Glucoside


5: Boosting efficacy Not all products can be multifunctional, and in those cases, formulators should ensure that the consumer is still getting value for their money. More than ever, consumers are looking to find where the value lies in their products, and one place to start is with the effects on skin. Brands should ensure that their products have good efficacy in order to justify the cost of the products and reassure consumers that they work as intended.


Clinical trials are the gold standard


to assess but these incur costs which are often prohibitive for the final formula. Instead, brands often conduct user trials on their formulation, with self-assessment questionnaires throughout the trial, to gauge whether the product works and if consumers see a noticeable benefit. These still come at a price, and formulators need to be confident that their user trials will


have positive results, which can be used in the promotion and marketing of the final product. The key to achieving this is to use actives ingredients with robust supporting data, and ingredients which can help to boost the actives effects. Baycusan C 1000 (by Covestro) is such a


material; a high performing film former which has been shown to boost the effects of several well-known actives in clinical tests. Seven


20% *** ***


BRIGHTENING (combintation with vitamin C. %)


2% Ascorbyl Glucoside 1% Col-Frag Remastered™ + Ascorbyl Glucoside


8% *** *


13% *** **


17% *** ***


21% *** ***


21% *** ***


26% *** ***


47


www.personalcaremagazine.com


May 2023 PERSONAL CARE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119